

Press release

22-08-2006, 08h30

KBC Private Equity invests EUR 1.5 m in Peakadilly NV

KBC Private Equity invests EUR 1.5m (USD 1.9m) in Belgian-based Peakadilly, the predictive biomarkers company. Peakadilly has raised a total of EUR 8.5m (USD 10.6m) in the final close of its Series A and bringing the total raised to EUR 14.5m (USD 18.4m).

Investors in the second close of the series A financing were GIMV, Life Science Partners (LSP), who led the series A round, KBC Private Equity, KBC Private Equity Fund Biotech and Baekeland II-fonds, the venture capital fund of the Ghent University. LSP were an investor in the first close alongside Johnson and Johnson Development Corporation.

The Company has implemented an innovative protein biomarker discovery technology that will transform the potential of protein biomarkers in molecular diagnostics and drug discovery and development. The proceeds of the financing will be used to increase the capacity of Peakadilly's protein biomarker discovery operation based on its proprietary MASStermind™ technology, enabling it to expand its relationships with pharma and diagnostic companies and to accelerate development of its own diagnostic and pharmacodiagnostic products. The Company has already secured a series of granted patents and revenue-generating projects with pharma.

About Peakadilly

Peakadilly was founded in late 2004 to exploit the protein biomarker discovery technology developed at VIB and the University of Ghent. In this short time, it has successfully implemented the technology and won revenue generating projects with big pharma. It applies the technology both to third party projects and to its own projects for developing a new generation of diagnostics and pharmacodiagnostic products. www.peakadilly.com

About KBC Private Equity

KBC Private Equity (www.kbcpe.com) provides development capital to and finances buy-outs of medium-sized companies in Belgium and Central and Eastern Europe. Boasting an experienced team of 23 people, it has more than 60 active investments with a market value in excess of 400 million EUR. KBC PE aims to become one of the leading private equity providers in its home markets. As an active shareholder with a long-term perspective, KBC PE is involved in taking strategic decisions and providing support to management teams.

Els Hubloux, Investment Manager, t: +32 2 429 04 25, e: els.hubloux@kbcpe.be